Simris Group AB

SIMRIS B

SE0008091664

Food Processing

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2024-07-05 pm EDT			5-day change	1st Jan Change
0.15 ^SEK	0.00%		-7.98%	-33.33%

Jun. 28	Simris Group AB Appoints Jonathan Royce as Members of the Board	CI
May. 27	Simris Group AB Announces Robert Quandt Declines Re-Election as Member of Board	CI

Simris Alg : interim report January - March 2021

May 07, 2021 at 04:30 am EDT

INCREASED ACTIVITIES IN NEW BUSINESS VERTICALS, NEW E-COMMERCE PLATFORM LAUNCHED

Simris Alg AB (publ) (FNSE:SIMRIS) has published its financial results for January - March 2021.

MSEK	Jan-Mar 2021	Jan-Mar 2020	Jan-Dec 2020
Net sales	0.492	0.265	2.166
Operating results	-7.462	-6.859	-23.694
Earnings before tax	-6.853	-6.486	-25.537
Net cash from operating activities	-7.478	-5.980	-19.485
Cash at end of period	8.463	1.641	16.512

Net sales were 0.492 MSEK (0.265) during the quarter. Net sales in the US were 0.308 MSEK (0.128).
The operating result was -7.462 MSEK (-6.859).
Christoffer Tell was appointed CFO.
Three business verticals were presented - SIMRIS BIOMIMETICS for cosmetics and pharmaceuticals, SIMRIS NOVEL FOODS for new food ingredients, and consumer brand SIMRIS for omega-3 supplements.
New e-commerce platforms were launched on simris.com for the US market and eu.simris.com for Sweden and the EU.
EFSA, the EU Food Safety Authority, granted an extension of the deadline to submit requested additional information to Simris Alg's application for authorisation under the Novel Food Regulation. New deadline is September 1, 2021.

SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD

The company presents a new development plan including new product candidates and upcoming milestones. New board members proposed to the AGM by the nomination committee will strengthen company management to realise the company's potential.
Simris Alg signs a five-year agreement with Anhalt University of Applied Sciences in Germany (AUAS) for the development of new biologically active substances from microalgae for advanced skincare. The collaboration increases Simris Alg's R&D capacity and aims to accelerate product development within the Simris Biomimetics business vertical.

COMMENT FROM THE CEO: FIRST STEPS IN NEW MARKETS

Those who have followed Simris Alg for a while have surely noticed the significant changes in our business which we implemented during the last quarter. Having successfully developed our platform from lab to industrial scale and taken our first products to market, we have now entered the next phase for real. Here, Simris continues to lead the development of microalgae biotechnology through our new business verticals, in particular Simris Biomimetics. Biologically active ingredients from microalgae for advanced skincare are aimed at a global market worth well over USD 500 billion, meaning we are sitting on a unique gold mine with almost untapped commercial potential. The first quarter also saw a pleasing increase for our e-commerce in the United States, following the launch of our new online store. Continued growth here is important to attract the right partner to operate our US sales of Simris® Algae Omega-3 in the future. Hence, we are excited and look forward to our new board of directors, which will play a key role in realising the potential of Simris moving forward. Spring has arrived!

The full version of the report is available in Swedish at www.simrisalg.se/investerare

FOR MORE INFORMATION, PLEASE CONTACT:
Fredrika Gullfot, CEO Simris
Tel: +46 761 345 474, email: gullfot@simris.com

ABOUT SIMRIS ALG AB (PUBL)
Simris Alg is a multi-awarded pioneer business developing bioactive substances from algae. The company's purpose and business is to save endagered marine habitats by producing raw materials from microalgae, instead of fish and other marine animals. Simris operates in three business areas: SIMRIS BIOMIMETICS (skincare and pharmaceuticals), SIMRIS NOVEL FOODS (new dietary ingredients), and the SIMRIS consumer brand targeted to the global lifestyle, beauty and wellness markets. Simris Alg's shares are traded on the Nasdaq First North Growth Market with ticker SIMRIS and ISIN SE0008091664. Certified Adviser is Mangold Fondkommission AB, phone +46 (0)8-503 015 50 and email ca@mangold.se.

https://news.cision.com/simris-alg/r/simris-alg-interim-report-january---march-2021,c3342773

https://mb.cision.com/Main/14177/3342773/1414480.pdf

https://news.cision.com/simris-alg/i/fredrika-gullfot-at-algae-farm,c2910661

https://news.cision.com/simris-alg/i/simris-coloured-algae-species-circle,c2910662

Latest news about Simris Group AB

Simris Group AB Appoints Jonathan Royce as Members of the Board	Jun. 28	CI
Simris Group AB Announces Robert Quandt Declines Re-Election as Member of Board	May. 27	CI
Simris Group AB Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15	CI
Simris Group AB Enters into Amended Agreement to Extend the Term of the Flexible Funding Facility with The Brand Laboratories FZ	Apr. 15	CI
Simris Group AB announced that it expects to receive ?1.15 million in funding from The Claremont Trust, Mountain High Trust, The Brand Laboratories FZE and other investors	Mar. 13	CI
Simris Group AB Announces CEO Changes	Mar. 12	CI
Simris Group AB Resolves to Temporarily Pause Production Operations At Its Microalgae Facility in Hammenhög, Sweden	Mar. 06	CI
Simris Group AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 28	CI
Simris Group AB Signs Head of Terms for an Offtake Agreement Valued At Minimum ?2 Million / SEK 22 Million	Jan. 10	CI
Simris Group AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Simris Appoints Reviate LLC as Exclusive Distributor	Nov. 07	CI
Simris Group AB announced that it has received SEK 2.9295 million in funding	23-10-29	CI
Simris Group AB Confirms New Patent Application from Its Adc-Payload Platform	23-08-02	CI
Simris Group AB Announces Executive Changes	23-07-28	CI
Simris Group AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-24	CI
Simris Group AB announced that it expects to receive SEK 2.9295 million in funding	23-05-28	CI
Simris Alg AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-08	CI
Simris Group AB Broadens Distribution of Its Reformulated Algal Omega-3 Products	23-04-28	CI
Simris Alg AB Auditor Raises 'Going Concern' Doubt	23-04-16	CI
Simris Alg AB Enters into Bridge Loan Agreement with the Brand Laboratories FZ	23-03-06	CI
Simris Alg AB has Changed its Name to Simris Group AB	23-03-06	CI
Simris Alg AB Signs Partnership Agreement with Lonza Ltd to Promote its ADC Payload Technology	23-02-28	CI
Simris Alg AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-15	CI
Simris Alg AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-09	CI
Simris Alg AB (OM:SIMRIS B) acquired 100% of the shares in Cyano Biotech GmbH.	22-08-24	CI

Chart Simris Group AB

Duration

Period

More charts

Company Profile

Simris Alg AB is a Sweden-based company, which is primarily engaged in the special foods and wellbeing products industry. The Company operates as a manufacturer of dietary supplements and specialty foods. The Company's products are based on algae-plants that live in water, such as seaweed, phytoplankton and kelp. These products are rich of Omega-3 oils and made from natural ingredients. The Company offers a wide range of algae-based supplements and foods, among them are Simris Algae Omega-3 Original, Simris Algae Omega-3 for Mothers, Simris Algae Omega-3 for Athletes, Finest Chlorella, Sundried Spirulina, Boosting Astaxanthin, Chlorella Crispies, Flower Power Algae Tea, Sun Candy Algae Tea and other.

Sector

Food Processing

Calendar

2024-08-13 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Special Foods & Wellbeing Products

	1st Jan change	Capi.
SIMRIS GROUP AB	-33.33%	4.97M
ZHEJIANG NHU COMPANY LTD.	+13.33%	8.17B
BELLRING BRANDS, INC.	+6.62%	7.71B
CSPC INNOVATION PHARMACEUTICAL CO., LTD.	-19.26%	4.44B
THE SIMPLY GOOD FOODS COMPANY	-8.54%	3.59B
BYHEALTH CO., LTD	-20.61%	3.14B
XIAMEN KINGDOMWAY GROUP COMPANY	-12.55%	1.2B
HERBALIFE LTD.	-26.47%	1.14B
JAMIESON WELLNESS INC.	-7.63%	888M
USANA HEALTH SCIENCES, INC.	-17.95%	857M